
https://www.science.org/content/blog-post/fish-nor-fowl
# Fish Nor Fowl (Oct 2011)

## 1. SUMMARY  
The author reflects on the “grey zone” of chemical synthesis that sits between the milligram‑scale work of a typical medicinal‑chemistry bench and the kilogram‑scale operations of a pilot or commercial plant.  While a chemist can comfortably make a few tens of grams of a compound using standard glassware (round‑bottom flasks, rotary evaporators, silica columns), moving to the 100‑ to 500‑gram range becomes awkward: glassware is heavy and unwieldy, solvent‑removal capacity is strained, and many reactions that run smoothly on a gram scale (e.g., hydrogenations) start to fail or require cumbersome batch‑splitting.  The piece points out that the industry has good solutions at the very small and very large ends, but there is a shortage of dedicated, versatile equipment for this intermediate scale—especially for hydrogenation, which is trivial on a gram scale but labor‑intensive at a few hundred grams.

## 2. HISTORY  
**Equipment development** – Over the decade after 2011 a number of vendors introduced purpose‑built “medium‑scale” reactors.  Commercial high‑pressure hydrogenation vessels (e.g., Parr, H‑Cube, and newer continuous‑flow hydrogenators from ThalesNano, Syrris, and Vapourtec) now routinely handle 100 g–1 kg batches with automated pressure, temperature, and gas‑flow control.  These systems are marketed specifically to process‑chemistry groups that need to bridge the bench‑to‑pilot gap.

**Flow chemistry adoption** – Continuous‑flow platforms have become mainstream in many pharma process‑development labs.  Flow hydrogenation, in particular, allows a 300‑g load to be processed continuously through a packed‑bed catalyst cartridge, eliminating the need for large batch reactors and reducing solvent consumption.  By the mid‑2020s, most large‑medicinal‑chemistry groups reported at least one flow hydrogenation unit in their labs.

**Outsourcing and CRO services** – The rise of specialized contract research organizations (CROs) offering “scale‑up chemistry” services has also mitigated the gap.  CROs maintain dedicated pilot‑scale equipment (10 g–5 kg) and can run hydrogenations, oxidations, and other transformations on demand, allowing companies to avoid purchasing expensive intermediate‑scale hardware.

**Process‑chemistry culture** – Academic curricula and industry training programs have increasingly emphasized “process chemistry” as a distinct skill set.  This cultural shift means that medicinal chemists are more aware of scale‑up constraints early in a project, often designing routes that are amenable to medium‑scale equipment from the outset.

**Remaining challenges** – Despite these advances, the fundamental ergonomics described in the article persist: handling large glassware, solvent waste, and safety considerations for high‑pressure hydrogen still require careful engineering.  The market for truly modular, “plug‑and‑play” 200‑g hydrogenators remains niche, and many labs still resort to batch‑splitting for very specific chemistries.

## 3. PREDICTIONS  
The article does not contain explicit forecasts, but it implicitly predicts that the lack of medium‑scale equipment (especially for hydrogenation) would be a bottleneck.  The subsequent reality can be evaluated as follows:

- **Prediction:** *Dedicated medium‑scale hydrogenation equipment will be scarce, forcing chemists to split batches.*  
  **Outcome:** Partially true.  By ~2018‑2020, several manufacturers released 100 g–1 kg hydrogenation reactors, reducing the need for manual batch splitting.  However, for highly specialized substrates or very high‑pressure conditions, batch splitting is still common.

- **Prediction:** *The gap between benchtop and pilot‑plant will remain “hard” to bridge.*  
  **Outcome:** The gap has narrowed thanks to flow reactors and modular high‑pressure vessels, but it has not disappeared.  Safety, solvent handling, and equipment cost still make the 100‑g to 1‑kg range a distinct engineering challenge.

- **Prediction (implicit):** *Process‑chemistry tools will evolve to handle the “grey zone.”*  
  **Outcome:** Accurate.  The rise of continuous‑flow platforms, automated pressure reactors, and CRO scale‑up services directly addresses the grey zone described.

## 4. INTEREST  
Rating: **6/10**  
The piece captures a genuine, long‑standing pain point in medicinal‑chemistry workflow and foreshadows the later emergence of flow and modular equipment, making it moderately interesting for historians of chemical process development.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20111027-fish-nor-fowl.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_